Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ Transplant Subjects with Epstein-Barr Virus Associated Post-Transplant Lymphoproliferative Disease after Failure of Rituximab or Roituximab and Chemotherapy